Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:CLLS NASDAQ:MOLN OTCMKTS:MRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.13-2.4%$9.68$3.75▼$11.54$149.79M2.7244,739 shs55,967 shsCLLSCellectis$2.66-1.8%$1.82$1.10▼$3.24$150.63M3.03345,848 shs81,518 shsMOLNMolecular Partners$3.63+4.2%$3.71$3.36▼$7.60$140.51M1.1995 shs1,281 shsMRMDMariMed$0.10-11.5%$0.09$0.07▼$0.29$42.56M3.02454,401 shs672,337 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-2.35%+0.22%-14.43%+22.88%+912,999,900.00%CLLSCellectis-1.85%+5.98%+65.22%+66.25%+31.03%MOLNMolecular Partners+2.26%-1.52%+1.26%-11.59%-40.08%MRMDMariMed-11.47%-1.53%+10.79%+1.58%-42.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition1.662 of 5 stars3.50.00.00.02.40.80.0CLLSCellectis2.2194 of 5 stars3.53.00.00.01.32.50.0MOLNMolecular Partners2.1626 of 5 stars3.84.00.00.00.60.00.6MRMDMariMed0.7534 of 5 stars0.03.00.00.02.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00119.06% UpsideCLLSCellectis 3.00Buy$4.0050.38% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00231.03% UpsideMRMDMariMed 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MRMD, CLLS, MOLN, and ACOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$2.93M49.94N/AN/A$2.59 per share3.53CLLSCellectis$49.22M3.00N/AN/A$1.75 per share1.52MOLNMolecular Partners$2.23M65.57N/AN/A$3.99 per share0.91MRMDMariMed$157.96M0.24$0.02 per share5.05$0.16 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.20N/A∞N/AN/A-65.83%-48.21%8/14/2025 (Confirmed)CLLSCellectis-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%N/AMOLNMolecular Partners-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)MRMDMariMed-$12.16M-$0.03N/A∞N/A-10.14%-10.35%-3.08%N/ALatest MRMD, CLLS, MOLN, and ACOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025H1 2025MOLNMolecular Partners-$0.53N/AN/AN/AN/AN/A8/14/2025Q2 2025ACOGAlpha Cognition-$0.84N/AN/AN/A$2.32 millionN/A8/4/2025Q2 2025CLLSCellectis-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 million5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83CLLSCellectis0.581.381.67MOLNMolecular PartnersN/A15.2815.28MRMDMariMed1.211.050.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/ACLLSCellectis63.90%MOLNMolecular Partners26.55%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%CLLSCellectis16.41%MOLNMolecular Partners5.93%MRMDMariMed18.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million13.78 millionN/ACLLSCellectis29055.58 million46.46 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableMRMDMariMed260390.43 million316.29 millionNot OptionableMRMD, CLLS, MOLN, and ACOG HeadlinesRecent News About These CompaniesMariMed Inc. (MRMD) Q2 2025 Earnings Call TranscriptAugust 7 at 11:01 PM | seekingalpha.comMariMed (MRMD) Q2 EPS Jumps to PositiveAugust 6 at 12:11 AM | fool.comMariMed Inc. (MRMD) Reports Break-Even Earnings for Q2August 6 at 8:06 PM | zacks.comMariMed Reports Second Quarter 2025 EarningsAugust 6 at 5:00 PM | globenewswire.comMariMed (MRMD) Projected to Post Quarterly Earnings on WednesdayAugust 5 at 3:23 AM | americanbankingnews.comMariMed’s Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT HoldingsJuly 31, 2025 | finance.yahoo.comMariMed's Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT HoldingsJuly 31, 2025 | globenewswire.comCORRECTION -- MariMed Expands Access to Top-Selling Betty’s Eddies Brand in MaineJuly 14, 2025 | uk.finance.yahoo.comMariMed Expands Access to Top-Selling Betty’s Eddies Brand in MaineJuly 14, 2025 | finance.yahoo.comCORRECTION -- MariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Expands Access to Top-Selling Betty's Eddies Brand in MaineJuly 14, 2025 | globenewswire.comMariMed Announces Second Quarter 2025 Earnings DateJuly 8, 2025 | globenewswire.comMariMed Statement Regarding the Commencement of Adult-Use Cannabis Sales in Delaware on August 1stJuly 1, 2025 | globenewswire.comMariMed Inc. (MRMD) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comMariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | uk.finance.yahoo.comMariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMay 29, 2025 | globenewswire.comEarnings call transcript: Marimed’s Q1 2025 revenue flat, stock edges upMay 9, 2025 | investing.comMariMed Inc. (PNK:MRMD) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comMariMed Inc (MRMD) Q1 2025 Earnings Call Highlights: Strategic Expansion Amidst Market ChallengesMay 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRMD, CLLS, MOLN, and ACOG Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.13 -0.22 (-2.35%) As of 08/7/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Cellectis NASDAQ:CLLS$2.66 -0.05 (-1.85%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.78 +0.12 (+4.51%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Molecular Partners NASDAQ:MOLN$3.62 +0.15 (+4.17%) Closing price 08/7/2025 03:57 PM EasternExtended Trading$3.68 +0.05 (+1.41%) As of 08/7/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.MariMed OTCMKTS:MRMD$0.10 -0.01 (-11.47%) As of 08/7/2025 03:55 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
